News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
253 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (17535)
Month
January (4450)
February (4428)
March (5683)
April (4545)
May (5703)
June (4805)
July (3912)
August (4762)
September (4260)
October (3860)
November (4837)
December (2683)
Day
1 (375)
2 (349)
3 (253)
4 (26)
5 (31)
6 (262)
7 (275)
8 (242)
9 (213)
10 (132)
11 (8)
12 (10)
13 (190)
14 (224)
15 (168)
16 (184)
17 (128)
18 (4)
19 (3)
20 (85)
21 (267)
22 (199)
23 (205)
24 (113)
25 (10)
26 (5)
27 (194)
28 (228)
29 (213)
30 (209)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Drug Development
BMS Picks up High Potential NSCLC Drug in $4.1B Turning Point Acquisition
Bristol Myers Squibb announced Friday that it is acquiring San Diego-based Turning Point Therapeutics in a deal totaling about $4.1 billion.
June 3, 2022
·
3 min read
·
Mark Terry
Drug Development
Sapience, Intensity, Kazia and Transcenta Tout Early Success at ASCO
Four life sciences companies posted previews of their respective programs ahead of the American Society of Clinical Oncology (ASCO) annual meeting on June 5, 2022.
June 3, 2022
·
3 min read
·
Vanessa Doctor, RN
Drug Development
FDA Extends Review for Amylyx ALS Drug to September
Amylyx Pharmaceuticals shared news that the FDA has extended the review period for AMX0035, a combination drug treatment with the potential to treat patients with ALS.
June 3, 2022
·
2 min read
·
Jazmine Colatriano M.S.
Drug Development
FDA Action Alert: Acer & Relief, Sanofi & Regeneron, Pfizer-BioNTech & Moderna and Rhythm
June is starting off with a number of important dates for the FDA, including an advisory committee meeting to discuss COVID-19 vaccines in children as young as six months.
June 3, 2022
·
3 min read
·
Mark Terry
Drug Development
New Biogen/Ionis Data Suggests ALS Drug Effective Upon Earlier Initiation
Biogen and Ionis Pharmaceuticals have announced results from the Phase III VALOR trial and an open-label extension (OLE) trial of tofersen.
June 3, 2022
·
4 min read
·
Mark Terry
Employer Resources
How to Keep Top Talent During Inflation
In order to stay afloat while maintaining a competitive edge, many life science companies are going to have to get creative in order to keep up with rising salaries and inflation.
June 3, 2022
·
5 min read
·
Franklin Carpenter
Business
Athersys Culls 70% of Staff in Effort to Prioritize MultiStem Programs
Shares of Cleveland-based Athersys, Inc. are plunging Friday after the company announced a strategic restructuring that will result in the slashing of 70% of its workforce.
June 3, 2022
·
2 min read
·
Alex Keown
Scientists Reset the Clock on Aging through Gene Manipulation
While tools to reverse age-related cellular dysfunction haven’t yet reached the masses, two research studies have emerged this week that hint at progress.
June 3, 2022
·
3 min read
·
Jazmine Colatriano M.S.
Business
Merck KGaA Strikes $550M Deal with Proxygen in Latest Protein Degradation Deal
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
June 3, 2022
·
2 min read
·
Alex Keown
Business
Sanofi and Immunocore Pair High Potential Molecules for Metastatic Skin Cancers
Sanofi will study its SAR444245 in combination with Immunocore’s KIMMTRAK in HLA-A*02:01 positive patients with advanced unresectable or metastatic skin cancers.
June 3, 2022
·
3 min read
·
Mark Terry
1 of 26
Next